p16/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population

Modern Pathology

Volumn 29, Issue 8, 2016, Pages 870-878

  Luttmer, Roosmarijn ^a   Dijkstra, Maaike G ^a   Snijders, Peter J F ^a   Berkhof, Johannes ^a   Van Kemenade, Folkert J ^b   Rozendaal, Lawrence ^a   Helmerhorst, Theo J M ^b   Verheijen, René H M ^c   Ter Harmsel, W Abraham ^d   Van Baal, W Marchien ^e   Graziosi, Peppino G C M ^f   Quint, Wim G V ^g   Spruijt, Johan W M ^a   Van Dijken, Dorenda K E ^h   Heideman, Danïlle A M ^a   Meijer, Chris J L M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d Roosevelt Clinic   (Netherlands)

^e Flevo Hospital   (Netherlands)

^f ST ANTONIUS HOSPITAL   (Netherlands)

^g DDL DIAGNOSTIC LABORATORY   (Netherlands)

^h ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PROTEIN P16; CYCLIN DEPENDENT KINASE INHIBITOR 2A; P16 PROTEIN, HUMAN;

ADULT; ARTICLE; COLPOSCOPY; CYTOLOGY; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; ADOLESCENT; AGED; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; EMERGENCY HEALTH SERVICE; GENETICS; HUMAN PAPILLOMAVIRUS DNA TEST; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NETHERLANDS; OUTPATIENT; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PRECANCER; PROSPECTIVE STUDY; REPRODUCIBILITY; UTERINE CERVIX CARCINOMA IN SITU; VAGINA SMEAR; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; NETHERLANDS; OUTPATIENTS; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; TRIAGE; VAGINAL SMEARS; YOUNG ADULT;

EID: 84965026288     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2016.80     Document Type: Article

References (34)

1. Steenbergen RD, Snijders PJ, Heideman DA, et al. Clinical implications of (epi)genetic changes in HPVinduced cervical precancerous lesions. Nat Rev Cancer 2014; 14: 395-405.
2. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
3. Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPVbased screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014; 383: 524-532.
4. Dijkstra MG, Van Niekerk D, Rijkaart DC, et al. Primary hrHPV DNA testing in cervical cancer screening: How to manage screen-positive women?. a POBASCAM trial substudy. Cancer Epidemiol Biomarkers Prev 2014; 23: 55-63.
5. Rijkaart DC, Berkhof J, van Kemenade FJ, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 2012; 130: 602-610.
6. Massad LS, Einstein MH, Huh WK, et al. 2012 Updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2013; 17: S1-27.
7. Castle PE, Stoler MH, Wright TC, et al. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 2011; 12: 880-890.
8. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048-1056.
9. von Knebel Doeberitz M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 2002; 38: 2229-2242.
10. Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2008; 17: 2536-2545.
11. Petry KU, Schmidt D, Scherbring S, et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 dual-stained cytology. Gynecol Oncol 2011; 121: 505-509.
12. Carozzi F, Gillio-Tos A, Confortini M, et al. Risk of highgrade cervical intraepithelial neoplasia during followup in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2013; 14: 168-176.
13. Wentzensen N, Schwartz L, Zuna RE, et al. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res 2012; 18: 4154-4162.
14. Schmidt D, Bergeron C, Denton KJ, et al. p16/ki-67 dualstain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol 2011; 119: 158-166.
15. Allia E, Ronco G, Coccia A, et al. Interpretation of p16 (INK4a) /Ki-67 dual immunostaining for the triage of human papillomavirus-positive women by experts and nonexperts in cervical cytology. Cancer Cytopathol 2015; 123: 212-218.
16. Luttmer R, De Strooper LM, Berkhof J, et al. Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in high-risk HPV-positive women of a gynecologic outpatient population (COMETH study). Int J Cancer 2016; 138: 992-1002.
17. Hesselink AT, Heideman DA, Steenbergen RD, et al. Combined promoter methylation analysis of CADM1 and MAL: An objective triage tool for high-risk human papillomavirus DNA-positive women. Clin Cancer Res 2011; 17: 2459-2465.
18. Jacobs MV, Snijders PJ, Van den Brule AJ, et al. A general primer GP5+/GP6+-mediated PCR-enzyme immunoassay method for rapid detection of 14 highrisk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997; 35: 791-795.
19. Schmitt M, Bravo IG, Snijders PJ, et al. Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 2006; 44: 504-512.
20. Luttmer R, Berkhof J, Dijkstra MG, et al. Comparing triage algorithms using HPV DNA genotyping, HPV E7 mRNA detection and cytology in high-risk HPV DNApositive women. J Clin Virol 2015; 67: 59-66.
21. Hanselaar AG. Criteria for organized cervical screening programs. Special emphasis on The Netherlands program. Acta Cytol 2002; 46: 619-629.
22. Uijterwaal MH, Polman NJ, Witte BI, et al. Triaging HPV-positive women with normal cytology by p16/ Ki-67 dual-stained cytology testing: baseline and longitudinal data. Int J Cancer 2015; 136: 2361-2368.
23. Uijterwaal MH, Witte BI, Van Kemenade FJ, et al. Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: crosssectional and longitudinal outcome study. Br J Cancer 2014; 110: 1579-1586.
24. Tang NS, Tang ML, Chan IS. On tests of equivalence via non-unity relative risk for matched-pair design. Stat Med 2003; 22: 1217-1233.
25. Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009; 124: 516-520.
26. Trimble CL, Piantadosi S, Gravitt P, et al. Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res 2005; 11: 4717-4723.
27. Ostör AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993; 12: 186-192.
28. Ikenberg H, Bergeron C, Schmidt D, et al. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: Results of the PALMS study. J Natl Cancer Inst 2013; 105: 1550-1557.
29. Kisser A, Zechmeister-Koss I. A systematic review of p16/Ki-67 immuno-Testing for triage of low grade cervical cytology. Br J Obstet Gynaecol 2015; 122: 64-70.
30. Ordi J, Sagasta A, Munmany M, et al. Usefulness of p16/ Ki67 immunostaining in the triage of women referred to colposcopy. Cancer Cytopathol 2014; 122: 227-235.
31. Wentzensen N, Fetterman B, Castle PE, et al. p16/Ki-67 dual stain cytology for detection of cervical precancer in HPV-positive women. J Natl Cancer Inst 2015; 107: djv257.
32. Moriarty AT, Nayar R, Arnold T, et al. The Tahoe Study: bias in the interpretation of papanicolaou test results when human papillomavirus status is known. Arch Pathol Lab Med 2014; 138: 1182-1185.
33. Bergeron C, Giorgi-Rossi P, Cas F, et al. Informed cytology for triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial. J Natl Cancer Inst 2015; 107: dju423.
34. Overmeer RM, Louwers JA, Meijer CJ, et al. Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPVpositive women. Int J Cancer 2011; 129: 2218-2225.